Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

Cyberonics net sales increase 13% to $53.7M for second quarter 2012

Cyberonics, Inc. today announced results for the quarter ended October 28, 2011.

19 Nov 2011

FDA accepts VIVUS' Qnexa NDA for filing and review

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa to treat obesity. The company resubmitted the NDA on October 17, 2011.

4 Nov 2011

Thyroidectomy reduces snoring associated with obstructive sleep apnea

Obstructive sleep apnea, caused by narrowing or blockage of the airways when a person is asleep affects about 20% of the population. Typically a person with OSA will begin snoring loudly on falling asleep. If not treated, obstructive sleep apnea (OSA) can increase a person's risk of death. It is not clear whether an enlarged thyroid gland, known as a goiter, can worsen cause or worsen symptoms of OSA by compressing the airway.

29 Oct 2011

Apnex Medical's HGNS System receives CE Mark approval for treatment of OSA

Apnex Medical, Inc., has received CE Mark approval for its Hypoglossal Nerve Stimulation System for use by people who suffer from obstructive sleep apnea.

28 Oct 2011

VIVUS announces Qnexa NDA resubmission for treatment of obesity

VIVUS, Inc. today announced that the company has resubmitted the New Drug Application (NDA) for Qnexa to the U.S. Food and Drug Administration.

18 Oct 2011

NovaSom enters unique agreement with HealthAmerica to treat sleep disorders

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for obstructive sleep apnea (OSA) management, today announced it has entered a preferred relationship to aid HealthAmerica with managing its sleep disorder diagnostic expenses.

11 Oct 2011

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS, Inc. today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

17 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

Philips to launch first sleep apnea mobile app at ESC 2011 congress

Royal Philips Electronics will provide clinicians from across the globe with a glimpse of future innovations designed to advance cardiac care, including the current management of cardiovascular disease (CVD) and associated cardiac conditions, during the 2011 Congress of the European Society of Cardiology (ESC), which opens today in Paris.

From Philips Healthcare 29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

CPAP withdrawal leads to return of obstructive sleep apnea

The benefits of continuous positive airway pressure machines (CPAP) for patients with obstructive sleep apnea (OSA) are quickly reversed when the therapy is withdrawn, according to Swiss research.

12 Aug 2011

Continuous positive airway pressure machine more effective for sleep apnea patients

Among the treatments for obstructive sleep apnea, the effectiveness of a nighttime-breathing machine called a "CPAP" was backed by the strongest evidence, and a mouthpiece worn at night was also shown to be effective, according to a new report funded by HHS' Agency for Healthcare Research and Quality.

9 Aug 2011

VIVUS announces additional data from phase 3 QNEXA studies on obesity

VIVUS, Inc. today announced that additional data from the phase 3 QNEXA studies will be presented today during the American Association of Diabetes Educators (AADE) meeting in Las Vegas, NV.

6 Aug 2011

Study: Compression stockings may improve OSA in patients with chronic venous insufficiency

Wearing compression stockings may be a simple low-tech way to improve obstructive sleep apnea in patients with chronic venous insufficiency, according to French researchers.

4 Aug 2011

FDA grants IDE approval for Apnex HGNS System to treat obstructive sleep apnea

Apnex Medical, Inc., received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a clinical study to evaluate the safety and effectiveness of its Hypoglossal Nerve Stimulation System to treat obstructive sleep apnea.

3 Aug 2011

Weight-loss programs a waste of time: Expert opinion

According to obesity expert and University of Melbourne professor of medicine Joseph Proietto the high failure rate of weight-loss programs could be explained by growing evidence that an obese person’s body is programmed to regain any weight that is lost. He said that authorities are wasting money on campaigns urging people to exercise and eat healthy food since obesity is “''physiologically defended”.

31 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

VIVUS to present topiramate exposure, birth defect data at IEC

VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.

20 Jul 2011

Ventus Medical launches Provent Sleep Apnea Therapy in India

Ventus Medical is pleased to announce the Indian launch of its proprietary Provent Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea.

20 Jul 2011

Lap Band surgery less expensive than other obesity-related treatments

By being safe, minimally invasive, and extremely effective, the Lap Band has become one of the most accessible means for obese individuals with a BMI of 35 or higher to shed their excess weight and lead healthier lives.

16 Jul 2011